Research Sample bioBank

Can’t find what you’re looking for? Contact us.

Or, need help ordering? 805.528.4341

Filter Samples By:

Get Weekly Research Sample Updates in your Inbox:

Hepatitis C (HCV) Genotype 2 Clinical Research Samples

Discovery Life Sciences provides the highest quality Hepatitis C (HCV) Genotype 2 Clinical Research Samples and Residual Diagnostic Specimens from the Life Science Industry’s only convenient online, open access Biobank. 

  • All Hepatitis C (HCV) Genotype 2 Sample Orders are Packaged for Delivery within 24 Hours. 
  • All Specimens Ethically Obtained, De-Identified and provided with Highly Annotated Demographic and Clinical Data.
  • Select from an HHS/OHRP Compliant Biorepository following ISBER/BBRB Guidelines.
  • Packaged in Compliance with all UN Regulations (6.2) and U.S. DOT Hazmat regulations. 
Showing 31 of 31 total samples
 (0)
Checkout
Advanced Data View:
Showing 31 of 31 total samples
Buy
Product IDSampleOriginMatrixVial (ml)QuantityPriceAgeGenderEthnicityStorage TempSample DateTest 1Test Data 1Sample Detail 1Test 2Test Data 2Sample Detail 2Test 3Test Data 3Product
Details
Price
Buy
Additional Information 1Additional Data 1Additional Information 2Additional Data 2Additional Detail 2Additional Information 3Additional Data 3Additional Information 4Additional Data 4Additional Detail 4Additional Information 5Additional Data 5Additional Detail 5Additional Information 6Additional Data 6Additional Detail 6Additional Information 7Additional Data 7Additional Detail 7
DLS12-0210Hepatitis C (HCV) Genotype 2ItalySerum1.003.00$95.0059 YMWhite<-70°C13-Dec-12Abbott Realtime PCR 168,883 IU/mLSiemens TruGene HCV2$95.003-series HepB VaccineNoIs Subject on Anti-Viral Therapy / TreatmentNoAcquired Infection CategoryDental CareSymptomsJoint painAdditional TestingALT: 45; AST: 54; ALP: 87; LDH: 470; Bilirubin: 1.96; Serum Creatinine: 0.7 mg/dL; Hepatocellular carcinomaHepatitis Serology Resultanti HCV+ (Abbott)
DLS12-0213Hepatitis C (HCV) Genotype 2ItalySerum1.002.00$95.0058 YFWhite<-70°C04-Feb-13Abbott Realtime PCR 1,152,951 U/mLSiemens TruGene HCV2$95.003-series HepB VaccineNoIs Subject on Anti-Viral Therapy / TreatmentNoAcquired Infection CategoryTransfusionSymptomsFatigue; Abdominal painAdditional TestingALT: 659; AST: 283; ALP: 56; LDH: 388; Bilirubin: 0.86; Serum Creatinine: 0.62 mg/dL; Chronic HepatitisHepatitis Serology Resultanti HCV+ (Abbott)
DLS12-6273Hepatitis C (HCV) Genotype 2ItalySerum1.004.00$95.0073 YMWhite<-70°C12-Apr-13Abbott Realtime PCR2,048,660 U/mLSiemens TruGene HCV2a/2c$95.003-series HepB VaccineNoIs Subject on Anti-Viral Therapy / TreatmentNoAcquired Infection CategoryHousehold ContactSymptomsFatigue; JaundiceAdditional TestingALT: 24; AST: 31; Serum Creatinine: 0.74 mg/dL; Chronic HepatitisHepatitis Serologyanti HCV+ (Abbott)
DLS12-6274Hepatitis C (HCV) Genotype 2ItalySerum1.008.00$95.0054 YFWhite<-70°C10-May-13Abbott Realtime PCR499,000 U/mLSiemens TruGene HCV2a/2c$95.003-series HepB VaccineNoIs Subject on Anti-Viral Therapy / TreatmentNoAcquired Infection CategoryDental Care; Household ContactSymptomsSleep disturbancesAdditional TestingALT: 19; AST: 24; Chronic HepatitisHepatitis Serologyanti HCV+ (Abbott)
DLS12-6279Hepatitis C (HCV) Genotype 2ItalySerum1.0010.00$95.0077 YMWhite<-70°C26-Jul-13Abbott Realtime PCR224 U/mLSiemens TruGene HCV2a/2c$95.003-series HepB VaccineNoIs Subject on Anti-Viral Therapy / TreatmentNoAcquired Infection CategorySurgerySymptomsFatigue; JaundiceAdditional TestingALT: 45; AST: 65; Chronic HepatitisHepatitis Serologyanti HCV+ (Abbott)
DLS12-6280Hepatitis C (HCV) Genotype 2USASerum1.004.00$95.0057 YMWhite<-70°C25-Jan-13Roche cobas2,994,740 IU/mLInnogenetics Versant HCV2$95.003-series HepB VaccineYes Is Subject on Anti-Viral Therapy / TreatmentNoAcquired Infection CategoryIV Drug AbuseSymptomsFatigueAdditional TestingALT: 155; AST: 189; ALP: 125; Bilirubin: 1.7; Serum Creatinine: 0.72 mg/dLHepatitis SerologyHep A Total Ab-; Hep BsAg-; Hep Bc Total Ab+
DLS13-16674Hepatitis C (HCV) Genotype 2ItalySerum1.002.00$95.0060 YMWhite< -70C26-Jul-13Abbott RealTime PCR1,150,000 U/mLSiemens TruGene HCV2$95.003-series HepB VaccineNoIs Subject on Anti-Viral Therapy / TreatmentNoAcquired Infection CategoryDental CareSymptomsFatigue Additional TestingALT: 135; AST: 114; ALP: 335; Bilirubin: 0.79; Serum Creatinine: 0.75 mg/dL; Chronic HepatitisHepatitis Serologyanti HCV+2009
DLS14-05318Hepatitis C (HCV) Genotype 2VietnamSerum1.009.00$95.0033 YMAsian< -70C06-Jun-14Roche cobas11,100,000 copies/mLReal-Time PCR2$95.003-series HepB VaccineNoIs Subject on Anti-Viral Therapy / TreatmentYesTenofovir 300 mg; Lamivudine 150 mg; Efavirenz 600 mgAcquired Infection CategorySexual Transmission SymptomsNo symptomsAdditional TestingALT: 143; AST: 97; LDH: 203; Bilirubin: 9.8 umol/LHepatitis SerologyHBsAg-; Anti HCV+ (Elisa)Co-InfectionsHIV+2013
DLS14-05323Hepatitis C (HCV) Genotype 2VietnamSerum1.0014.00$95.0070 YMAsian< -70C10-Apr-14Roche cobas1,600,000 cps/mLReal-Time PCR2$95.003-series HepB VaccineNoIs Subject on Anti-Viral Therapy / TreatmentNoAcquired Infection CategoryUnknown SymptomsDecreased appetite; Fatigue; Abdominal pain; Jaundice; DepressionAdditional TestingALT: 110; AST: 68; Bilirubin: 67.3 umol/L; Serum Creatinine: 0.9 mg/dL; HCV 2009
DLS14-05350Hepatitis C (HCV) Genotype 2VietnamSerum1.0014.00$95.0056 YMAsian< -70C11-Apr-14Roche cobas5,320,000 copies/mLReal-Time PCR2$95.003-series HepB VaccineNoIs Subject on Anti-Viral Therapy / TreatmentNoAcquired Infection CategoryUnknown SymptomsDecreased appetite; Fatigue; Abdominal pain; Jaundice; Sleep disturbancesAdditional TestingALT: 40; AST: 17; ALP: 78; Bilirubin: 100 umol/L; Serum Creatinine: 1.1 mg/dL
DLS14-05407Hepatitis C (HCV) Genotype 2VietnamSerum1.007.00$95.0055 YFAsian< -70C21-Mar-14Roche cobas31,000 copies/mLReal-Time PCR2$95.003-series HepB VaccineNoIs Subject on Anti-Viral Therapy / TreatmentNoAcquired Infection CategoryUnknown SymptomsDecreased appetite; Fatigue; Joint pain; Sleep disturbancesAdditional TestingALT: 48; AST: 34; ALP: 74; Bilirubin: 10.2 umol/L; Serum Creatinine: 0.6 mg/dL
DLS12-0161Hepatitis C (HCV) Genotype 2RussiaSerum1.003.00$95.0026 YFU/A< -70C15-Oct-12Abbott Realtime PCR480,000 IU/mL5-Oct-12Abbott Real Time PCR2b5-Oct-12$95.003-series HepB VaccineYesIs Subject on Anti-Viral Therapy / TreatmentNoAcquired Infection CategoryUnknownSymptomsDecreased appetite, Fatigue, DepressionAdditional TestingALT: 698; AST: 256; ALP: 112; Bilirubin: 19.0; Serum Creatinine 0.068 mg/dL 5-Oct-12Hepatitis Serology Resultanti HCV (G)+ (Abbott)5-Oct-12
DLS14-05351Hepatitis C (HCV) Genotype 2VietnamSerum1.005.00$95.0065 YMAsian< -70C16-Sep-14Roche cobas84,600 IU/mL5-Sep-14Real-Time PCR213-Oct-14$95.003-series HepB VaccineNoIs Subject on Anti-Viral Therapy / TreatmentNoAcquired Infection CategoryUnknownSymptomsDecreased appetite; FatigueAdditional TestingALT: 459; AST: 1579; Bilirubin: 46.8 umol/L; Serum Creatinine: 0.8 mg/dL 3-Sep-14Hepatitis Serology ResultAnti HCV + (Cobas)28-Aug-2014
DLS16-67401Hepatitis C (HCV) Genotype 2VietnamSerum1.004.00$95.0052 YMAsian<-70C10-Oct-16Roche cobas5,030,000 IU/mL6-Oct-16Real-Time PCR212-Oct-16$95.003-series HepB VaccineNoIs Subject on Anti-Viral Therapy / TreatmentNoAcquired Infection CategoryUnknown SymptomsFatigue; Abdominal painAdditional TestingALT: 67 U/L; AST: 74 U/L; Bilirubin: 8.2 umol/L; Serum Creatinine: 86 umol/L5-Oct-16Hepatitis SerologyAnti HCV + (cobas 6000E and Architect)6-Sep-16Co-InfectionsN/A
DLS17-048711Hepatitis C (HCV) Genotype 2FranceCitrated Plasma1.001.00$95.00 U/AU/A<-70C21-Jan-09Roche Cobas351,786 IU/mLInnogenetics INNO-LIA2a | 2cAbbott Prism HCV7.97$95.00Elisa4.968
DLS0025501Hepatitis C (HCV) Genotype 2ItalySerum1.003.00$95.0066 YMWhite<-70C01-Dec-17Roche cobas15,000,000 IU/mL28-Sep-17Siemens TruGene HCV 5NC2a28-Sep-17HCV Date of Diagnosis7-Apr-10$95.003-series HepB VaccineNoIs Subject on Anti-Viral Therapy / TreatmentNoAcquired Infection CategoryU/ASymptomsNo symptomsAdditional TestingALT: 38 U/L | AST: 38 U/L | ALP: 60 U/L | Bilirubin: 0.4 mg/dL | Serum Creatinine: 0.6 mg/dL | Chronic Hepatitis C28-Sep-17Diasorin Liaison Serology ResultsHBsAg-, HBsAb-, HBcAb-, HBeAg-, 28-Sep-17Co-InfectionsNone
DLS16-72180Hepatitis C (HCV) Genotype 2ItalySerum1.0011.00$95.0060 YFWhite<-70C13-Oct-17Roche cobas1,910,000 IU/mL21-Sep-17Siemens TruGene HCV 5NC1b21-Sep-17HCV Date of Diagnosis9-Jun-10$95.003-series HepB VaccineNoIs Subject on Anti-Viral Therapy / TreatmentNoAcquired Infection CategoryU/ASymptomsNo symptomsAdditional TestingALT: 38 U/L | AST: 42 U/L | | Bilirubin: 1.35 mg/dL | Serum Creatinine: 0.26 mg/dL | Chronic Hepatitis C5-Sep-17Diasorin Liaison Serology ResultsHBsAg-, HBsAb+, HBcAb-, 5-Sep-17Co-InfectionsNone
DLS16-72202Hepatitis C (HCV) Genotype 2ItalySerum1.002.00$95.0069 YMWhite<-70C18-Oct-17Roche cobas6,380,000 IU/mL15-Feb-17Siemens TruGene HCV 5NC2b10-Oct-16HCV Date of Diagnosis4-Mar-16$95.003-series HepB VaccineNoIs Subject on Anti-Viral Therapy / TreatmentNoAcquired Infection CategoryU/ASymptomsFatigueAdditional TestingALT: 38 U/L | AST: 38 U/L | Bilirubin: 0.6 mg/dL | Serum Creatinine: 1.1 mg/dL | Chronic Hepatitis C26-May-17Diasorin Liaison Serology ResultsHBsAg-, HBsAb+, HBcAb-, 25-May-17Co-InfectionsNone
DLS16-72204Hepatitis C (HCV) Genotype 2ItalySerum1.009.00$95.0079 YFWhite<-70C28-Sep-17Roche cobas750,000 IU/mL28-Oct-16Siemens TruGene HCV 5NC2a8-May-17HCV Date of Diagnosis28-Oct-16$95.003-series HepB VaccineNoIs Subject on Anti-Viral Therapy / TreatmentNoAcquired Infection CategoryU/ASymptomsFatigueAdditional TestingALT: 40 U/L | AST: 40 U/L | Bilirubin: 0.5 mg/dL | Serum Creatinine: 1.0 mg/dL | Chronic Hepatitis C11-Oct-17Diasorin Liaison Serology ResultsHBsAg-, HBsAb+, HBcAb+, 6-May-17Co-InfectionsNone
DLS0025519Hepatitis C (HCV) Genotype 2ItalySerum1.009.00$95.0076 YFWhite<-70C27-Nov-17Roche cobas830,000 IU/mL12-Sep-17Siemens TruGene HCV 5NC2a12-Sep-17HCV Date of Diagnosis5-Apr-17$95.003-series HepB VaccineNoIs Subject on Anti-Viral Therapy / TreatmentNoAcquired Infection CategoryU/ASymptomsNo symptomsAdditional TestingALT: 36 U/L | AST: 35 U/L | Bilirubin: 0.4 mg/dL | Serum Creatinine: 0.7 mg/dL | Chronic Hepatitis C12-Sep-17Diasorin Liaison Serology ResultsHBsAg-, HBsAb+, HBcAb-, 4-Dec-17Co-InfectionsNone
DLS16-72195Hepatitis C (HCV) Genotype 2ItalySerum1.006.00$95.0071 YMWhite<-70C27-Jul-17Roche cobas8,760,000 IU/mL30-May-17Siemens TruGene HCV 5NC2a30-May-17HCV Date of Diagnosis4-May-17$95.003-series HepB VaccineNoIs Subject on Anti-Viral Therapy / TreatmentNoAcquired Infection CategoryU/ASymptomsNo symptomsAdditional TestingALT: 68 U/L | AST: 110 U/L | 27-Jun-2017 | Bilirubin: 0.7 mg/dL | Serum Creatinine: 1.3 mg/dL | Chronic Hepatitis C4-May-17Diasorin Liaison Serology ResultsHBsAg-, HBsAb+, HBcAb-, HBeAb-, 30-May-17Co-InfectionsNone
DLS16-72215Hepatitis C (HCV) Genotype 2ItalySerum1.001.00$95.0067 YFWhite<-70C13-Oct-17Roche cobas9,100,000 IU/mL19-May-17Siemens TruGene HCV 5NC219-May-17HCV Date of Diagnosis19-May-17$95.003-series HepB VaccineNoIs Subject on Anti-Viral Therapy / TreatmentNoAcquired Infection CategoryU/ASymptomsFatigueAdditional TestingALT: 38 U/L | AST: 38 U/L | | Bilirubin: 0.6 mg/dL | Serum Creatinine: 0.94 mg/dL | Chronic Hepatitis C23-Oct-17Diasorin Liaison Serology ResultsHBsAg-, HBsAb-, HBcAb-, 19-May-17Co-InfectionsNone
DLS0025516Hepatitis C (HCV) Genotype 2ItalySerum1.009.00$95.0049 YFWhite<-70C23-Jan-18Roche cobas5,430,000 IU/mLHCV Viral LoadGenotype2a11-Nov-153-series HepB VaccineNo$95.00Acquired Infection CategoryU/AIs Subject on Anti-Viral Therapy / TreatmentNoCurrent SymptomsNo symptomsAdditional TestingALT: 120 U/L | AST: 70 U/L | Bilirubin: 0.4 mg/dL | Creatinine: 0.5 mg/dL | Chronic Hepatitis C22-Sep-17Hepatitis SerologyHBsAg- | HBsAb- | HBcAb- | (CMIA)25-Oct-17Co-InfectionsNone
DLS0025515Hepatitis C (HCV) Genotype 2ItalySerum1.009.00$95.0080 YMWhite<-70C23-Jan-18Roche cobas2,790,000 IU/mLHCV Viral LoadGenotype2a14-Nov-173-series HepB VaccineNo$95.00Acquired Infection CategoryU/AIs Subject on Anti-Viral Therapy / TreatmentNoCurrent SymptomsFatigueAdditional TestingALT: 320 U/L | AST: 268 U/L | Chronic Hepatitis C16-Oct-17Hepatitis SerologyHBsAg- | HBsAb- | HBcAb- | HBeAg- | HBeAb- (CMIA)16-Oct-17Co-InfectionsNone
DLS0025521Hepatitis C (HCV) Genotype 2ItalySerum1.009.00$95.0070 YMWhite<-70C09-Feb-18Roche cobas16700000 IU/mLHCV Viral LoadGenotype210-Nov-153-series HepB VaccineNo$95.00Acquired Infection CategoryU/AIs Subject on Anti-Viral Therapy / TreatmentNoCurrent SymptomsFatigueAdditional TestingLDH: 161 U/L | Bilirubin: 0.4 mg/dL | Creatinine: 1.34 mg/dL | Chronic Hepatitis C12-Feb-18Hepatitis SerologyHBsAg- | HBsAb- | HBcAb+ | (CMIA)12-Feb-18Co-InfectionsNone
DLS0083213Hepatitis C (HCV) Genotype 2ItalySerum1.0013.00$95.0073 YMWhite<-70C12-Jun-18Roche cobas8,900 IU/mLHCV Viral LoadGenotype2a/2c10-Oct-173-series HepB VaccineNo$95.00Acquired Infection CategoryTransfusionIs Subject on Anti-Viral Therapy / TreatmentNoCurrent SymptomsNo symptomsAdditional TestingBilirubin: 0.63 mg/dL | Creatinine: 1.29 mg/dL | Chronic Hepatitis C8-Mar-18Hepatitis SerologyHBsAg- | HBsAb- | HBcAb- | (CMIA)10-Oct-17Co-InfectionsNone
DLS0083212Hepatitis C (HCV) Genotype 2ItalySerum1.006.00$95.0055 YMWhite<-70C16-May-18Roche cobas9,560,000 IU/mLHCV Viral LoadGenotype2a/2c10-Oct-143-series HepB VaccineNo$95.00Acquired Infection CategoryU/AIs Subject on Anti-Viral Therapy / TreatmentNoCurrent SymptomsNo symptomsAdditional TestingBilirubin: 1.3 mg/dL | Creatinine: 1.0 mg/dL | Chronic Hepatitis C11-May-18Hepatitis SerologyHBsAg- | HBsAb- | HBcAb- | (CMIA)11-May-18Co-InfectionsNone
DLS0083217Hepatitis C (HCV) Genotype 2ItalySerum1.002.00$95.0068 YFWhite<-70C04-Jul-18Roche cobas9,300,000 IU/mLHCV Viral LoadGenotype24-Jul-183-series HepB VaccineNo$95.00Acquired Infection CategoryU/AIs Subject on Anti-Viral Therapy / TreatmentNoCurrent SymptomsNo symptomsAdditional TestingBilirubin: 0.6 mg/dL | Creatinine: 1.2 mg/dL | Chronic Hepatitis C6-Jul-18Hepatitis SerologyHBsAg- | HBsAb- | HBcAb- | (CMIA)12-Feb-18Co-InfectionsNone
DLS0083215Hepatitis C (HCV) Genotype 2ItalySerum1.0011.00$95.0076 YFWhite<-70C22-Jun-18Roche cobas627,000 IU/mLHCV Viral LoadGenotype28-Jul-053-series HepB VaccineNo$95.00Acquired Infection CategoryU/AIs Subject on Anti-Viral Therapy / TreatmentNoCurrent SymptomsNo symptomsAdditional TestingBilirubin: 0.5 mg/dL | Creatinine: 0.9 mg/dL | Chronic Hepatitis C9-Jul-18Hepatitis SerologyHBsAg- | HBsAb- | HBcAb- | (CMIA)18-May-18Co-InfectionsNone
KHBR-1734Hepatitis C (HCV) Genotype 2USASerum1.251.00$95.0028 YMWhite<-70C17-Apr-18Roche COBAS | Taqman5,549,384HCV RNA PCR$95.00Freeze Date05.15.18HEP C+: Genotype 2b
KHBR-1738Hepatitis C (HCV) Genotype 2USASerum1.501.00$95.0025 YFWhite<-70C17-Apr-18Roche COBAS | Taqman319,473 HCV RNA PCR$95.00Freeze Date05.15.18HEP C+: Genotype 2b

Keep in mind that all the samples comprised in the Research Sample Biobank represent only a small number of the clinical research specimens available through our Discovery Partners™ clinical research programs. If you can’t find the specific sample type, specimen or biofluids you are looking for please make sure to call our client services group at 805.528.4341 - and ask how we can help support your project from resources available at active clinical sites.

Please read carefully before purchasing:

Clinical specimens for research use only.

Transmissible Infectious Risk! May be HIV, HBV and HCV REACTIVE or of unknown infectious agent test status. Materials provided are derived from human blood, tissue and other bio-fluids. Handle all samples as if capable of transmitting infectious agents. Practice good laboratory technique and dispose of in properly marked medical waste.

If you need help searching for a LARGER SAMPLE SET with specific data elements, please contact our Client Services group who can format Excel spreadsheets for a comprehensive review of all available samples: USA (805) 528-4341

These products are supplied without warranty for suitability for specific applications or analytical determinations.

Specimens and data will be may be used for general biomarker research, assay and instrument validation purposes only. All Research products identified as “Diagnostic Remnant Samples” are human biological materials leftover from routine laboratory analysis and are de-identified (coded) to protect subject confidentiality. Under OHRP definition 45 CFR 46.102(f) these coded specimens are not considered subjects for Human research requiring informed consent. Specimens cannot be used for whole genomic sequencing of genetic material. Research products designated as “Clinical Research Samples” by “type” are obtained from IRB approved research study protocols with informed consent obtained from each subject enrolled. Specimens cannot be used for whole genomic sequencing of genetic material.